

Final approvals received to commence Clinical Study at Joondalup Health Campus, WA

- Final approvals, including Ethics Committee approval, have been received for a comprehensive study of HMD's proprietary medical grade pregnancy monitor, HeraBEAT at Joondalup Health Campus.
- Study to evaluate usability, acceptability, accuracy and reliability of remote pregnancy monitoring using HeraBEAT
- Study aligns with HMD's strategy to partner with key opinion leaders and top tier healthcare providers to accelerate adoption and progresses HMD further towards commercialisation
- HMD is to provide the technology and clinicians at Joondalup Health Campus to provide study leadership, management and execution
- Recruitment of participants to commence shortly

HeraMED Limited (ASX:HMD) ("HeraMED" or the "Company"), a medical data and technology company leading the digital transformation of maternity care, is pleased to announce final approvals including Ethics Committee approval have been received to commence a comprehensive study to evaluate the clinical utility and acceptability of remote pregnancy monitoring using its proprietary medical grade foetal and maternal heart rate monitor, HeraBEAT (the "Study").

The study will also examine the usability, accuracy and reliability of the HeraBEAT device, initially in the antenatal clinic and then at home before recommending use in routine clinical protocols.

The HeraBEAT remote pregnancy monitoring device is one of the main features of HMD's comprehensive SaaS and IOT platform, HeraCARE and has already obtained TGA (Australia) and CE (Europe) approvals for over-the-counter home use as well as FDA 510K clearance for home use under prescription in the USA.

The study will be conducted at the Joondalup Health Campus in Perth, Western Australia and will be led by an experienced clinical and research team that specialises in innovative technology focused on Obstetrics and Pediatrics, as outlined below.

- Principal investigator, A/Professor Paul Porter, Consultant - Department of Pediatrics, Joondalup Health Campus and the lead and scientific founder of PHI group;
- The Department of Obstetrics, Joondalup Health Campus; and,
- The Department of Pediatrics, Joondalup Health Campus

As part of the Study, HeraMED is responsible for providing the technology, support and instructions for best practice usage and clinicians at Joondalup Health Campus are responsible for planning, leadership and execution, recruiting participants. As a result, ongoing costs have been optimised and made efficient.

The study is now going through registration on the Australia and New Zealand Clinical Trials Registry (ANZCTR), an administrative step that will not impact the commencement of the trial. Recruitment will commence imminently.

HeraMED has a broad global strategy of generating substantial clinical validation for its product offering which will establish it as the standard of care in remote, foetal and maternal wellbeing. Proving the value of HMD's technology in Australia will set a platform for greater local recognition which will underpin the Company's long-term commercial objectives.

CEO and Co-founder Mr David Groberman said: "This study is a significant step forward for the company and is aligned with our strategy, it is particularly important for our operational and commercial development as it firmly validates that expectant mothers are able to use our technology at home to obtain accurate remote pregnancy monitoring. This then allows the safe transition to a reduction in face-to-face antenatal visits whilst enhancing the overall prenatal experience for pregnant women.

We are committed to delivering on our long-term growth strategy and we continue to work with our partners in the key strategic regions we are heavily targeting to secure further clinical studies and move forward into the commercial stages of growth.”

This announcement has been authorised by the Board of HeraMED Limited.

-ENDS-

HeraMED Limited

CEO and Co-Founder

David Groberman

M: +972 52 6991188

E: David@hera-med.com

Company Secretary

Jonathan Hart

T: +61 2 8379 2961

E: Jonathan@hera-med.com

Media Enquiries

Melissa Hamilton

Media & Capital Partners

M: +61 4 1775 0274

E: Melissa.hamilton@mcpartners.com.au

About HeraMED Limited (ASX:HMD):

HeraMED is an innovative medical technology company leading the digital transformation of maternity care by revolutionising the prenatal and postpartum experience with its hybrid maternity care platform. HeraMED offers a proprietary platform that utilises hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence, big data and a digital social networking dashboard.

About HeraCARE

The Company's proprietary offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver better care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, allow healthcare professionals to provide the highest quality care and enable early detection and prevention of potential risks.